RhoVac AB

NGM:RHOVAC Stock Report

Market Cap: SEK 22.1m

RhoVac Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Lars Hedbys

Chief executive officer

SEK 191.6k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenure4yrs

Recent management updates

Recent updates

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

Feb 12
We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Aug 27
RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Mar 23
Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

Dec 08
We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

CEO

Lars Hedbys (65 yo)

less than a year

Tenure

SEK 191,610

Compensation

Mr. Lars Hedbys, Ph. D., served as Director at Hamlet Pharma AB (publ) until 2022. He serves as Independent Chairman of the Board of Directors at Scandinavian ChemoTech AB (publ) since 2020. He serves as D...

Board Members

NamePositionTenureCompensationOwnership
Lars Hedbys
Acting CEO & Director8yrsSEK 191.61kno data
Per Straten
Scientific Advisor & Co-Founderno datano datano data
Lars Hockenstrom
Director3yrsSEK 191.61kno data
Cristina Glad
Director8yrsSEK 160.69kno data
Gunnar Gardemyr
Chairman5yrsSEK 383.22kno data
Georg Holländer
Scientific Advisory Board2.3yrsno datano data
Anne Ridley
Member of Scientific Advisory Board2.9yrsno datano data
Per-Anders Abrahamsson
Scientific advisorno datano datano data
Klaus Brasso
Scientific Advisorno datano datano data

4.0yrs

Average Tenure

65.5yo

Average Age

Experienced Board: RHOVAC's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/01/18 07:19
End of Day Share Price 2023/01/18 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RhoVac AB is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonas PeciulisEdison Investment Research